Fecal Microbiota Transplantation in Alzheimer’s Disease: Mechanistic Insights Through the Microbiota–Gut–Brain Axis and Therapeutic Prospects
Microorganisms · 21.08.2025 · 13 (8) · 1956
DOI: 10.3390/microorganisms13081956 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Microorganisms, online erschienen am 21.08.2025. Verfasst von Jiayu Ren und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Health Science Center, Ningbo University, Ningbo 315211, China. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 157 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: One health Interdisciplinary Research Project, Ningbo University, National 111 Project of China, the Health Fund of Translational Biomedicine.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD), a prevalent neurodegenerative disorder in the aging population, remains without definitive therapeutic solutions. Emerging insights into the gut microbiota (GM) and its bidirectional communication with the central nervous system(CNS) through the microbiota–gut–brain axis (MGBA) have unveiled potential correlative mechanisms that may contribute to AD pathogenesis, though causal evidence remains limited. Dysregulation of GM composition (dysbiosis) exacerbates AD progression via neuroinflammation, amyloid-β (Aβ) deposition, and tau hyperphosphorylation (p-tau), while restoring microbial homeostasis presents a promising therapeutic strategy. Fecal microbiota transplantation (FMT), a technique to reconstitute gut ecology by transferring processed fecal matter from healthy donors, has demonstrated efficacy in ameliorating cognitive deficits and neuropathology in AD animal models. Preclinical studies reveal that FMT reduces Aβ plaques, normalizes tau phosphorylation, suppresses inflammasome activation, and restores microglial homeostasis through modulation of microbial metabolites and immune pathways. Although clinical evidence remains limited to case reports and small-scale trials showing potential therapeutic effect, safety concerns regarding long-term effects and protocol standardization necessitate further investigation. This review synthesizes current knowledge on GM–AD interactions, evaluates FMT’s mechanistic potential, and discusses challenges in translating this ancient practice into a cutting-edge AD therapy. Rigorous randomized controlled trials and personalized microbiota-based interventions are imperative to advance FMT from bench to bedside.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Public Health, Health Science Center, Ningbo University, Ningbo 315211, China.
ORCID-Profile: Qinwen Wang, Hang Hong, Chunlan Tang
Förderung
- One health Interdisciplinary Research Project, Ningbo University
- National 111 Project of China
- the Health Fund of Translational Biomedicine
- Health Fund of Translational Biomedicine
Zitieren
APA
Ren, J., Wang, Q., Hong, H., & Tang, C. (2025). Fecal Microbiota Transplantation in Alzheimer’s Disease: Mechanistic Insights Through the Microbiota–Gut–Brain Axis and Therapeutic Prospects. Microorganisms, 13(8), 1956. https://doi.org/10.3390/microorganisms13081956
Vancouver
Ren J, Wang Q, Hong H, Tang C. Fecal Microbiota Transplantation in Alzheimer’s Disease: Mechanistic Insights Through the Microbiota–Gut–Brain Axis and Therapeutic Prospects. Microorganisms. 2025;13(8):1956. doi:10.3390/microorganisms13081956
BibTeX
@article{Ren2025,
author = {Ren, Jiayu and Wang, Qinwen and Hong, Hang and Tang, Chunlan},
title = {Fecal Microbiota Transplantation in Alzheimer’s Disease: Mechanistic Insights Through the Microbiota–Gut–Brain Axis and Therapeutic Prospects},
journal = {Microorganisms},
year = {2025},
volume = {13},
number = {8},
pages = {1956},
doi = {10.3390/microorganisms13081956}
}
EUVIMED